BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer.

ABSTRACT:

Introduction

BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characterized by a poor prognosis and dismal median survival. Following successful outcomes with BRAF inhibition in BRAF mutant metastatic melanoma, this approach was evaluated in metastatic colorectal cancer (mCRC). The development and combination of targeted therapies against multiple signaling pathways has proved particularly successful, with improved survival and response rates.

Areas covered

This review addresses the development of therapeutic strategies with inhibitors targeting MAPK/ERK and

SUBMITTER: Ros J 

PROVIDER: S-EPMC7903827 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature